Stay updated on Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4, a minor technical update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded a Texas location under Locations and updated the revision to v3.3.3. Removed footer/related entries for HHS Vulnerability Disclosure, MedlinePlus Genetics, and Texas Locations.SummaryDifference0.4%

- Check38 days agoChange DetectedThe page now displays related-topic links for Prostate cancer and MedlinePlus Genetics, enhancing access to disease- and genetics-related information.SummaryDifference0.2%

- Check59 days agoChange DetectedRemoved related topics 'Prostate cancer' and 'MedlinePlus Genetics' and added the label 'Revision: v3.3.2'. This is a minor UI/content update and does not affect the study details.SummaryDifference0.2%

- Check66 days agoChange DetectedAdded Prostate cancer tag and related topic MedlinePlus Genetics to the page. Removed the government funding status notice.SummaryDifference0.6%

- Check73 days agoChange DetectedRemoved the topic label 'Prostate cancer' and the related topic 'MedlinePlus Genetics' from the page. This could affect topic-based navigation and the visibility of prostate cancer-related information on the study page.SummaryDifference0.2%

Stay in the know with updates to Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page.